Equity Overview
Price & Market Data
Price: $15.83
Daily Change: -$0.06 / 0.38%
Daily Range: $15.58 - $16.11
Market Cap: $800,147,776
Daily Volume: 273,557
Performance Metrics
1 Week: 4.70%
1 Month: -0.50%
3 Months: 10.93%
6 Months: 22.62%
1 Year: 48.78%
YTD: -1.98%
Company Details
Employees: 270
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.